The effects of macrophage colony-stimulating factor (M-CSF) on CD4 receptor expression, susceptibility to human immunodeficiency virus type 1 (HIV) infection, and anti-HIV activity of dextran sulfate and soluble-CD4 were studied in cultured, human primary macrophages. M-CSF stimulated macrophage cells to express the CD4 receptor, and this resulted in an increase of both the number of CD4' cells and the density of the receptor on the cell surface. M-CSF also significantty enhanced the susceptibility of macrophage cells to HIV infection. Interestingly, the anti-HIV activity of dextran sulfate and soluble-CD4 (two compounds that interfere with HIV-CD4 binding with different mechanisms) was re-
as dextran sulfate and soluble CD4.27,28 Interestingly, we found that the antiviral activity of both compounds is dramatically reduced in macrophages stimulated with M-CSF, but not in those stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte colonystimulating factor (G-CSF), two other bone marrow stimulatory cytokines.
MATERIALS AND METHODS
Cells. Peripheral blood obtained from HIV-negative donors was enriched for mononuclear cells (PBMCs) by centrifugation over Fi-col1 Hypaque. Macrophages were obtained by adherence of PBMCs to plastic, as previously de~cribed.'~.*~ Cells obtained by this method are greater than 95% pure, as determined by nonspecific esterase activity.16 Each experiment was performed using PBMCs from a single donor.
Virus. A monocytotropic strain of HIV-l, human T-lymphotrophic virus type 111 (HTLV-IIIBa.L; gift of Drs S . Gartner , R.C. Gallo, and M. Popovic, National Cancer Institute, Bethesda, MD) was used. This will be referred to as HIV-lB,L. Supernatants from infected cultures of fresh macrophages were used as the source of HIV-lBa.L; these were filtered and stored in liquid nitrogen before use. Titration to determine infectivity was performed in a primary macrophage system as previously described." The titer of virus stock, expressed as 50% tissue culture infectious dose (TCID,,), was determined as previously de~cribed.~' Compounds. Soluble CD4 was obtained from Genentech Inc (San Francisco, CA). Dextran sulfate (molecular weight [MW] 8,000) and zidovudine (AZT) were purchased from Sigma (St Louis, MO). OKT4a, an antibody that reacts with the HIV-specific domain of CD4, was from Ortho Pharmaceuticals (Raritan, NJ). Recombinant M-CSF was kindly provided by Genetics Institute (Cambridge, MA) and contains 2 X 10' U/mg of protein; recombinant GM-CSF was obtained from Sandoz Research Institute (East Hanover, NJ) and contains 5.4 X 10' chronic myelogenous leukemia (CML) units per milligram of glycoprotein; recombinant G-CSF (Amgen Biologicals. Thousand Oaks, CA) had a specific activity of 1 X IOR U/mg protein.
Cyto$mrimetric analysis. Just after purification, l X lo6 macrophages were seeded in Petri dishes in 3 mL of complete medium with or without 1,000 U/mL M-CSF or 100 U/mL GM-CSF. On day 7, adherent cells were detached by 20 minutes of incubation with 0.2% EDTA, followed by vigorous pipetting. The expression of CD4 protein was assessed by flow cytometry using a fluoresceinated Leu3a + b monoclonal antibody (Becton Dickinson, Mountain View, CA). Paired isotype-specific control antibodies (Becton Dickinson) were run with each sample. Macrophages were differentiated from lymphocytes and dead cells on the basis of forward angle and 90" scatter, as previously described.''
Assay of antiviral activity. For the evaluation of the antiviral activity of dextran sulfate and soluble CD4, macrophage cells were plated at 1.5 X 105/mL in 48-well plates (Costar, Cambridge, MA) with or without 1,000 U/mL M-CSF or 100 U/mL GM-CSF. On day 7, cells were exposed to various concentrations of the compounds and 30 minutes later were exposed to 100 TCQ) HTV-l,,,. Appropriate mock-infected cultures were run as negative controls. Two hours after infection, macrophages were extensively washed to remove excess virus and cultivated in I mL of RPMI-1640 medium supptemented with 20% heat-inactivated fetal calf serum, 2 mmoll L L-glutamine, 50 U/mL penicillin, and 50 pg/mL streptomycin (complete medium) at 37°C in a humidified atmosphere of 5% CO, in air. Cells were washed and fed and the same concentrations of M-CSF, GM-CSF, and drugs as before were added every 7 days. Viral detection. HIV-p24 antigen production in supernatants was assessed by a sandwich enzyme-linked immunosorbent assay (ELISA; Abbott, Pomezia, Italy). The number of macrophages expressing the viral antigen p24 was evaluated by indirect immunofluorescence (IF). For this purpose, an anti-p24 monoclonal antibody (Biosoft, Paris, France) was used. The cells were directly processed in the well plates in which they were cultured. On day 21 after viral challenge, the cells were washed, dried in air, and fixed in methanol for I O minutes. The cultures were then processed as previously described." Results were evaluated by optical reading with a fluorescent microscope. At least 300 cells were counted for each sample.
Electron microscope (EM) analysis. For EM analysis, macrophage cells were processed and infected as described above. On day 21 after viral challenge, cells were fixed with 2.5% glutaraldehyde, detached by gentle scraping, collected by low-speed centrifugation, and postfixed in 1% Os04. After dehydration, specimens were embedded into Epon resin. Thin sections were stained with uranyl acetate and lead nitrate and observed under a Philips electron microscope. To evaluate the number of virus-expressing cells, 100 cells were counted for each sample.
Susceptibility assay. Normal or M-CSF-treated macrophages were infected with HIV-lB,L at different multiplicities of infection.
The HIV-1 ..., viral stock was serially diluted and macrophage cultures were infected in quadruplicate as described above. On day 21 after viral challenge, supernatants were tested for p24 antigen production.
Neutralization assay. A polyclonal rabbit antihuman M-CSF antibody (Genzyme) was used to neutralize M-CSF activity. Anti"-CSF antibody was diluted to a concentration of 1 mg/& and stored at -20°C until used. The neutralization assay was performed by preincubating for 2 hours at 37°C I .000 U of M-CSF with 50 pg of anti-M-CSF antibody.
Enzymatic amplijcation. Macrophages were infected as described above and detached from the wells 24 hours after viral challenge. DNA was extracted as previously de~cribed.'~ After ethidium bromide fluorescent quantitation of the amount of DNA, equivalent amounts of each sample were subjected to 30 cycles of polymerase chain reaction (PCR) amplification using either the HIV gag primer pair SK 38/39 or the HLA-DQa primer pair GH26/27. Amplified products, a 1 15-bp sequence in the gag region of the HIV genome, and a 242-bp fragment (or 239-bp fragments from some alleles) from the second exon of the HLA-DQa locus were specitically detected by the oligomer-hybridization procedure.?.' The SK 19 and RH 54 oligonucleotide probes were end-labeled with "P adenosine triphosphate as previously de~cribed.'~ X-ray films of polyacrylamide gels were quantified by analysis with an LKB UItrascan XL laser densitolneter (LKB-Phamacia, Rome. Italy).
Toxicity. Toxicity of dextran sulfate and soluble CD4 in macrophages was evaluated by trypan blue dye exclusion.
Protein determinution. Proteins were measured by the method of Lowry et a136 using bovine serum albumin as standard.
Cell count. Nuclei were extracted from macrophages by lysing buffer and counted in a cell counting chamber under a phase contrast microscope.
RESULTS

Enhancement of virus replication by cytokines.
Macrophages were exposed to 1,000 U/mL M-CSF, 100 U/mL GM-CSF, or 500 U/mL G-CSF and then challenged with HIV-1. Virus production was assessed as p24 gag protein release in the supernatants at various time points. In agreement with previously reported both M-CSF and GM-CSF potently enhanced the replication of HIV in macrophages as compared with control cells (Fig 1) . By contrast, G-CSF had no effect on HIV replication in macrophages, with the overall curve of virus production in supernatants being superimposable with that obtained in control macrophages.
CD4 expression in normal and M-CSF-treated macrophages. Macrophage cells cultured in the absence or in presence of M-CSF or GM-CSF were analyzed for CD4 expression at day 7 of culture. Figure 2A shows that, of the unstimulated LeuM3-positive monocytes, 56% f 13% expressed CD4 (mean channel difference 123). In contrast, 89% -+ 8% of M-CSF-treated macrophages showed CD4 expression (mean channel difference +52; Fig 2B) . To confirm the role of M-CSF in the induction of CD4 expression in macrophages, we performed a neutralization assay by using a specific antihuman M-CSF antibody. Figure 2C shows that the increased expression of CD4 induced by M-CSF on macrophages was abolished when M-CSF was preincubated with the anti-M-CSF antibody (63% -t 18% of positive cells, +30 mean channel difference). In contrast with M-CSF, GM-CSF treatment did not modify significatively the expression of CD4 on macrophages; 49 -t 10 GM-CSF-treated macrophages expressed CD4, with a mean channel difference of +19. These data indicate that M-CSF increases the number of macrophage cells expressing CD4 as well as the overall expression of this receptor.
Effect of M-CSF on HIV DNA formation. DNA was ex- Days of culture tracted from infected cultures 24 hours after viral challenge, a period that allows only one cycle of HIV repli~ation.~'
Comparable amplification ol' a fragment ol' HLA-DQa gene was obtained from each macrophage sample, suggesting that the same amount of DNA was subjected to amplification (not shown). HIV-DNA was detected in both untreated and M-CSF-treated macrophages. As shown in Fig 3 (lanes 6 and 7) , M-CSF increased the synthesis of HIV-DNA (2.200 I' 115 copies) compared with untreated cells. By contrast. GM-CSF, a cytokine that does not alter the expression of CD4 on macrophages (see above), does not induce any substantial modifications of the amount of HIV-DNA with respect to control macrophages (not shown).
We then evaluated whether the M-CSF-induced increased expression of CD4 had a causal role in modulating the enhancement of HIV-DNA synthesis. To assess this point, macrophage cultures were preincubated with different concentrations of OKT4a before viral challenge. IS0 pg/mL of the antibody had to be used to obtain a comparable inhibition in M-CSF-treated macrophages. These data suggest that there is a direct correlation between the M-CSF-induced increased expression of CD4 and the ability of HIV to enter within macrophage cells and to synthesize its DNA. to HIV infection was further investigated by infecting normal or M-CSF-treated macrophages with HIV at different muitiplicities of infection. As shown in Fig 4, infection of normal macrophages (as assessed by p24 production) was obtained with 100, 10, and 1 TCIDSo of the HIV-lBa.L stock. In contrast, M-CSF-treated macrophages could be infected with TCIDso as low as 0.01. When infected at the same multiplicities of infection, M-CSF-treated macrophages produced about 10-fold more extracellular virus than normal macrophages (Fig 4) . It has been reported that M-CSF may induce some replication of cultured macrophages." Thus, to further exclude that the enhanced susceptibility of M-CSF-treated macrophages to HIV infection (assessed as the production of extracellular virus) was the simple consequence of an increase in the number of target cells, we assessed the total number of cells (by counting the nuclei after cell lysis and by determining the amount of total cellular proteins) and the relative number of virus-expressing cells by EM and IF analysis. As shown in Table 1 , at day 21 of culture, M-CSF treatment was associated with an increase in the production of p24-antigen in the supernatants and in the number of virus-expressing cells with respect to untreated cells. However, no substantial differences were found between treated and untreated cells regarding the total number of cells ( Table 1 ). EM analysis also shows that, at a single-cell level, M-CSF treatment of macrophages was associated with an increased release of mature virus particles both in the extracellular compartment and in intracellular vacuoles with respect to untreated cells (Fig S) . Thus, overall data suggest that the increased replication of HIV in M-CSF-treated macrophages is not caused by the increased number of target cells.
Anti-HIV activity of dextran sulfate and soluble CD4 in normal and M-CSF-treated macrophages. The anti-HIV activity of dextran sulfate and soluble CD4, two compounds that interfere with the binding of HIV to the CD4 receptor, and that of AZT, a dideoxynucleoside that inhibits the activity of the virus-specific reverse transcriptase, were tested in normal and cytokine-treated macrophages.
As shown in Fig 6, complete inhibition of HIV replication (no p24 detected in the supernatants) was obtained in normal macrophages using 250 pg/mL dextran sulfate or S pg/mL soluble CD4, with a SO% inhibition being achieved by 50 pg/mL dextran sulfate and 1 pg/mL soluble CD4, respectively. M-CSF-treated macrophages required at least 100fold more dextran sulfate (5,000 pg/mL) to obtain only SO% inhibition of HIV replication, whereas a greater inhibition could not be achieved for the toxicity of higher concentrations of dextran sulfate. Also, complete inhibition of viral replication in M-CSF-treated macrophages could be achieved only with 25 pg/mL soluble CD4, ie, a concentration fivefold greater than that effective in control macrophages ( Fig 6) . Interestingly, the anti-HIV activity of AZT (0.1 pmol/L; a reverse transcriptase inhibitor) was identical in unstimulated and stimulated cells. Figure 6 also shows the antiviral activity of dextran sulfate, soluble CD4, and AZT in GM-CSF-treated macrophages. In agreement with previously published data,'' we found that GM-CSF increases the anti-HIV activity of AZT, whereas no differences were observed between GM-CSF-treated and control cells regarding the anti-HIV activity of dextran sulfate and soluble CD4. Thus, the downmodulation of the activity of dextran sulfate and soluble CD4 in macrophages seems to be peculiar of the treatment with M-CSF.
As a further control, we evaluated the effects of G-CSF (SO0 U/mL), a cytokine widely used in different clinical settings (including HIV-related diseases). In contrast to M-CSF or GM-CSF, G-CSF did not show any effect upon modulation of the activity of AZT or other antiviral compounds in macrophages (not shown). At the effective concentrations, neither dextran sulfate, soluble CD4, or AZT were toxic for macrophage cultures (not shown).
DISCUSSION
In this report, we show that M-CSF treatment stimulates cultured macrophages to increase the expression of the CD4 receptor. Also, the susceptibility of these cells to HIV infection is significatively enhanced by the treatment with M-CSF, whereas the antiviral activity of compounds that inhibit phage proliferation or differentiation per se. However, in agreement with previously reported data,'6.3n we found that GM-CSF, a cytokine that, similar to M-CSF, supports the long-term growth and differentiation of macrophages in vitro,".40 has no effect on CD4 expression. It has been reported that posttranslational changes affecting the conformation of the CD4 molecule cause internalization and reduced membrane insertment of CD4 in macrophages.41s42 Thus, it is possible that M-CSF directly acts by preventing such modifications and the consequent internalization of CD4.
The data we reported seem to indicate that the enhancement of CD4 expression induced by M-CSF in macrophages increases the number of cells potentially infectable by HIV. This is consistent with several reports showing that infection of macrophages is dependent on the degree of expression of CD4 at the moment of the infection.21"6 In addition, EM analysis suggests that M-CSF may stimulate the replication of HIV also at a single-cell level. Therefore, we cannot exclude that the increase in the production of mature virions observed in M-CSF-treated macrophages may also be related to an effect of this cytokine on some late steps of the HIV replication cycle.
In the case of GM-CSF (a cytokine that does not affect CD4 expression on macrophages), our results support the hypothesis that it enhances HIV replication in macrophages by upmodulating steps of virus replication later than retrotranscription. In this regard, it has been postulated that cytokines may upregulate the expression of HIV in macrophage cells by the induction of a cellular gene that, in turn, induces the promoter of HIV either through a cis mechanism that depends on the integration site of the provirus or by transacti-BERGAMlNl ET AL vating via a DNA-binding protein. A DNA-binding protein (NF-KB) has been described that binds to the HIV long terminal repeats in infected T lymphocytes and upregulates virus expre~sion.~~ Regarding G-CSF, our data show that this cytokine has no effects on HIV replication in macrophages. These data are similar to those reported in the literature by a number of groups and are consistent to the fact that G-CSF affects mainly the granulocyte lineage, whereas its specific receptor is poorly (if at all) expressed in mature macrophage^.'^.^'
The effects of M-CSF on CD4 expression and macrophage susceptibility to HIV could be responsible for the reduced antiviral activity of dextran sulfate and soluble CD4 observed in cytokine-treated macrophages. This hypothesis is also supported by the evidence we obtained that GM-CSF did not show any effect on both the expression of CD4 and the antiviral activity of dextran sulfate and soluble CD4. The ability of M-CSF to increase the overall expression of the CD4 receptor may directly reduce the activity of dextran sulfate, a compound that inhibits HIV replication by blocking the gp120 binding site on cellular CD4.28,45 Also, the enhanced susceptibility to HIV infection induced by M-CSF may reduce the antiviral activity of concentrations of soluble CD4 that sufficiently neutralize HIV infectivity in normal macrophages.
In contrast to tissue macrophages in lung, brain, and lymph nodes, blood monocytes are only rarely infected in AIDS patient^.^.^.^'.^' Moreover, it has been recently reported that in the early stage of the HIV infection there is a dichotomy between the number of infected monocytes in peripheral blood versus lymphoid tiss~e!~.~~ This enhanced susceptibility to HIV infection of tissue macrophages with respect to blood monocytes could be due, at least in part, to the effect of endogenous M-CSF. In this regard, it should be noted that bioassays performed on human blood have shown that endogenous M-CSF levels are similar to those used in this work (700 to 1,000 U/I~L).~".~' Moreover, it has been reported that, during experimentally induced bacterial infection in mice, the blood levels of M-CSF may increase from 700 to about 1,500 UlmL."
The role of macrophages in the pathogenesis of HIV infection has been overstressed over several years.'.'' Thus, therapeutic strategies used in the therapy of AIDS and related disorders should directly address the virus inhibition in this special target population. Dextran sulfate and soluble CD4 have been shown to be potent inhibitors of HIV replication in vitro.27.2n,4s,s~,s4 However, in vivo, both compounds have been consistently shown to be ineffective in AIDS The lack of clinical activity has been attributed to the existence of primary HIV isolates resistant to soluble CD4 neut r a l i z a t i~n~~.~~ or to inefficient absorption from the gastrointestinal tract for orally administered dextran sulfate." We suggest here that the lack of in vivo anti-HIV activity of dextran sulfate and soluble CD4 could be also caused by the effects of endogenous M-CSF on tissue macrophages.
New therapeutic strategies based on the use of sulfated polysaccharides, other than dextran sulfate, with improved absorption and less potent anticoagulant activity are currently under study.6',62 Because it is possible that endogenous M-CSF may be able to decrease the antiviral activity of most For personal use only. on November 16, 2017. by guest www.bloodjournal.org From compounds acting at the level of virus binding, to better predict the in vivo efficacy of these agents on the basis of their in vitro activity, it could be useful to perform selected antiviral assays also in M-CSF-stimulated macrophages systems before reaching clinical trials.
